Low-dose continuous terlipressin infusion is effective and safer than intravenous bolus injections in reducing portal pressure and control of acute variceal bleeding
- 21 December 2022
- journal article
- research article
- Published by Springer Nature in Hepatology International
- Vol. 17 (1) , 131-138
Abstract
Background and aims Continuous infusion of terlipressin is better tolerated, and equally effective at lower doses than intravenous boluses in type 1 hepatorenal syndrome. This approach in cirrhosis patients with acute esophageal variceal bleed was investigated by comparing the efficacy and adverse events of continuous versus bolus administration of terlipressin. Methods One hundred ten consecutive cirrhosis patients with acute esophageal variceal bleed (AEVB) were randomized to receive either terlipressin as bolus (BOL, n = 55), 2 mg every 4 h, or, continuous infusion (CONI, n = 55), 4 mg/24 h for 5 days. Hepatic venous pressure gradient (HVPG) was measured at baseline, 12 and 24 h and response to terlipressin was defined as > 10% decline from baseline. Results Baseline demographics, model for end-stage liver disease (MELD) and HVPG were comparable between groups. The primary objective of HVPG response at 24 h was achieved in significantly more patients in CONI than BOL group {47/55(85.4%) vs. 32/55(58.2%), p = 0.002}. Early HVPG response at 12 h was also higher in CONI group (71.5 vs. 49.1%, p < 0.01). Median dose of terlipressin was significantly lower {4.25 ± 1.26 mg vs. 7.42 ± 1.42 mg/24 h, p < 0.001)} and adverse events were fewer {20/55(36.3%) vs. 31/55(56.4%), p = 0.03} in the CONI than BOL group. Significantly higher incidence of very early rebleed was noted in BOL group {8/55 (14.5%) vs. 1/55, (1.8%), p = 0.03}. Baseline HVPG (OR 1.90, 95% CI = 1.25–2.89, p = 0.002) and MELD (OR 1.18, 95% CI = 0.99–1.41, p = 0.05) were predictors of rebleed. Conclusion “HVPG-tailored” continuous terlipressin infusion is more effective than bolus administration in reducing HVPG at a lower dose with fewer adverse events in cirrhotic patients. Clinical trial identifier NCT02695862.Keywords
This publication has 14 references indexed in Scilit:
- Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled studyHepatology, 2016
- Expanding consensus in portal hypertensionJournal of Hepatology, 2015
- A MELD-Based Model to Determine Risk of Mortality Among Patients With Acute Variceal BleedingGastroenterology, 2014
- Hemodynamic effects of continuous versus bolus infusion of terlipressin for portal hypertension: A randomized comparisonJournal of Gastroenterology and Hepatology, 2013
- Diagnosis and management of acute variceal bleeding: Asian Pacific Association for Study of the Liver recommendationsHepatology International, 2011
- Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapyJournal of Hepatology, 2008
- Acute Hemodynamic Effects of Octreotide and Terlipressin in Patients with Cirrhosis: A Randomized ComparisonAmerican Journal of Gastroenterology, 2005
- Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: A meta-analysisHepatology, 2002
- Somatostatin Treatment and Risk Stratification by Continuous Portal Pressure Monitoring During Acute Variceal BleedingGastroenterology, 2001
- Time profile of the haemodynamic effects of terlipressin in portal hypertensionJournal of Hepatology, 1997